Latest Regulatory Risk News

Nufarm Limited reported a solid half-year performance with a 3% revenue increase and a 40% jump in underlying EBIT, driven by strong crop protection sales and cost improvements. However, net debt rose 12%, reflecting investments in omega-3 production and seed technology expansion.

Lindian Resources has assured investors that its bauxite projects in Guinea remain untouched by recent government mining license cancellations, underscoring stable progress despite regulatory upheaval.

Peak Rare Earths Limited has agreed to be acquired by Ganzhou Chenguang Rare Earths New Material Co., Ltd., a subsidiary of Shenghe Resources, in a deal valuing Peak at A$150.5 million plus proceeds from a proposed entitlement offer. The transaction offers Peak shareholders a significant premium and aims to accelerate development of the Ngualla Rare Earth Project.

EDU Holdings Limited reported a remarkable turnaround in FY24 with record revenue and profit, yet faces ongoing regulatory headwinds prompting a proposed ASX delisting. The company’s strategic pivot focuses on domestic growth and operational agility.

EDU Holdings Limited plans to voluntarily delist from the ASX, citing low share liquidity and regulatory uncertainty in the international student market. The company proposes a substantial buy-back offer to provide shareholders with an exit opportunity ahead of delisting.

Botanix Pharmaceuticals clarifies its lead product Sofdra is unlikely to face price cuts under the proposed US executive order on drug pricing, citing its exclusive US market approval and distinct formulations abroad.

European Lithium Ltd has released compelling assay results from historical deep diamond drilling at its Tanbreez Rare Earth Project in Greenland, confirming high-grade rare earth oxides and significant gallium concentrations that support potential resource expansion.

Coronado Global Resources Inc. posted a $96.2 million net loss for Q1 2025, reflecting weak metallurgical coal prices and ongoing liquidity challenges. The company is navigating covenant waivers and pursuing refinancing amid market uncertainty.

Macquarie Group reported a 5% rise in full-year net profit to A$3.715 billion for FY25, driven by growth across its diversified businesses and a solid capital position. The group’s assets under management reached A$941 billion, supported by strong home loan and deposit growth.

PointsBet Holdings Limited has announced a scheme meeting for shareholders to vote on its proposed $1.06 per share acquisition by MIXI Australia, with an independent expert deeming the offer fair and reasonable amid a competing bid from betr Entertainment.

Mayne Pharma has announced the expiration of the US antitrust waiting period, a critical step forward in Cosette Pharmaceuticals' proposed acquisition. The transaction now moves closer to completion, pending other regulatory and shareholder approvals.

Spenda Limited has responded to an ASX price query following a notable rise in its share price and trading volume, denying any undisclosed material information while confirming ongoing confidential negotiations for virtual card and funding services.